CPT® Code 91318

1. Indications

The CPT® Code 91318 is indicated for the vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes coronavirus disease (COVID-19). The vaccine is specifically designed for use in pediatric patients aged 6 months through 4 years. It is intended to provide protection against the potentially severe and life-threatening effects of COVID-19, particularly in young children who may be at risk for serious illness from the virus.

• COVID-19 Prevention The vaccine is administered to prevent infection by the SARS-CoV-2 virus and to mitigate the risk of severe disease associated with COVID-19 in young children.

2. Procedure

The administration of the vaccine involves several key procedural steps to ensure safety and efficacy. First, the vaccine must be prepared by diluting the Pfizer pediatric vaccine with normal saline to achieve the correct dosage of 3 mcg in a 0.3 mL volume. This preparation is crucial for ensuring that the vaccine is safe and effective for the target age group. Next, the healthcare provider will select an appropriate site for intramuscular injection, typically in the thigh for infants and young children. The injection site should be cleaned with an antiseptic to minimize the risk of infection. Once the site is prepared, the vaccine is administered intramuscularly, allowing the lipid nanoparticles to facilitate the uptake of mRNA by the cells. After the injection, the healthcare provider may observe the patient for a short period to monitor for any immediate adverse reactions. It is important to document the administration details, including the date, time, and site of injection, as well as any reactions observed during the monitoring period.

• Step 1: Vaccine Preparation The vaccine is prepared by diluting the Pfizer pediatric vaccine with normal saline to achieve the appropriate dosage of 3 mcg in a 0.3 mL volume.
• Step 2: Site Selection and Preparation An appropriate site for intramuscular injection is selected, typically the thigh, and the site is cleaned with an antiseptic.
• Step 3: Vaccine Administration The vaccine is administered intramuscularly, allowing the lipid nanoparticles to facilitate the uptake of mRNA by the cells.
• Step 4: Post-Administration Monitoring The patient is observed for a short period to monitor for any immediate adverse reactions, and documentation of the administration details is completed.

3. Post-Procedure

After the administration of the vaccine, it is essential to monitor the patient for any immediate side effects or adverse reactions, which may include mild symptoms such as soreness at the injection site, fever, or fatigue. These reactions are typically short-lived and resolve on their own. Parents or guardians should be informed about potential side effects and advised on when to seek medical attention. Additionally, it is important to schedule any follow-up doses if required, as per the vaccination schedule recommended for the pediatric population. Documentation of the vaccination, including the lot number and expiration date of the vaccine, should be recorded in the patient's medical record to ensure proper tracking and compliance with vaccination protocols.